Seeking Alpha

Depomed (DEPO) says that the FDA's website shows that an Abbreviated New Drug Application for a...

Depomed (DEPO) says that the FDA's website shows that an Abbreviated New Drug Application for a generic version of Zipsor has been submitted. DEPO hasn't received a Paragraph IV certification with respect to the filing and doesn't know the identity of the party that filed. The company says Zipsor is protected by five patents, all of which are listed in the FDA’s Orange Book, and it intends to vigorously enforce its intellectual property rights relating to the drug.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs